Status:
COMPLETED
A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures
Lead Sponsor:
GlaxoSmithKline
Collaborating Sponsors:
Adelphi Real World
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
Brief Summary
Previous publications have indicated that Allergic Rhinitis (AR) patients suffering from both ocular and nasal symptoms have a greater burden of illness and lower quality of life than patients sufferi...
Detailed Description
* Allergic rhinitis (AR) is a common inflammatory condition of the upper respiratory tract, nasal cavity and eyes affecting up to 20% of the population in the United States and Europe. The bothersome ...
Eligibility Criteria
Inclusion
- Patient
- Current Seasonal Allergic Rhinitis sufferer (based on physician judgement)
- Currently receiving prescribed INS treatment (no other treatment restrictions apply)
- Have consumed at least one full prescription on the specified INS treatment
- No comorbid Asthma or COPD diagnosis
- Informed Consent
Exclusion
- None specified
Key Trial Info
Start Date :
July 10 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT01199757
Start Date
July 10 2009
End Date
August 1 2009
Last Update
August 14 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.